Clinical Report: Carbimazole's ‘Triple-Hit’ in a Patient with Vasculitis

Overview

Revise to include a clearer timeline of the patient's symptoms and treatment response.

Background

Carbimazole is commonly used to treat hyperthyroidism, but its association with drug-induced ANCA-associated vasculitis (AAV) is increasingly recognized. The coexistence of AAV and antiphospholipid syndrome (APS) presents significant management challenges due to the competing risks of hemorrhage and thrombosis. Understanding these associations is crucial for optimizing treatment strategies in affected patients.

Data Highlights

Key Findings

• The patient developed microscopic polyangiitis with diffuse alveolar hemorrhage after 15 years of carbimazole treatment.
• Imaging revealed ground-glass opacities consistent with pulmonary hemorrhage.
• Laboratory tests confirmed myeloperoxidase–ANCA-associated vasculitis and elevated IgM anticardiolipin antibodies indicating APS.
• Rapid initiation of plasmapheresis was crucial for stabilizing the patient's pulmonary condition.
• The patient achieved remission after treatment with pulse methylprednisolone and intravenous cyclophosphamide.
• Carbimazole was safely reintroduced at a lower dose without recurrence of vasculitis.

Clinical Implications

This case underscores the importance of recognizing drug-induced AAV in patients receiving carbimazole, particularly when presenting with respiratory symptoms. Clinicians should be prepared to initiate plasmapheresis and immunosuppressive therapy promptly to manage such complex cases effectively.

Conclusion

The report illustrates a rare but significant complication of carbimazole therapy, highlighting the need for vigilance in monitoring patients for signs of vasculitis and APS. Effective management can lead to favorable outcomes even in challenging clinical scenarios.

References

1. P. Thulasinadh, Cureus, 2023 -- Case Report Shows Carbimazole's ‘Triple-Hit’
2. The ASCO Post — Carfilzomib-Based Triplet Yields ‘Unprecedented’ Duration of Remission in Relapsed Myeloma
3. The Journal of Clinical Endocrinology & Metabolism — TRIAC Treatment Mitigates Hyperthyroid Symptoms and Reduces T4, T3 Levels, and Metabolic Rate in Patients with Resistance to Thyroid Hormone β
4. Blood Cancer Journal — Development of chronic inflammatory demyelinating polyneuropathy (CIDP) following cilta-cel treatment
5. the asco post — Rare Secondary Cancer After CAR T-Cell Therapy Successfully Treated, Case Report Shows
6. Carbimazole-Induced Diffuse Alveolar Hemorrhage
7. PEXIVAS Main Results
8. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome